Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib

Giacomo Coltro; Giulio Capecchi; Margherita Maffioli; Francesco Mannelli; Barbara Mora; Alessandro Atanasio; Alessandra Iurlo; Chiara Maccari; Mirko Farina; Elena Nacca; Marianna Caramella; Leonardo Signori; Miriam Borella; Lorenza Bertù; Maria Esposito; Paola Guglielmelli; Francesco Passamonti; Alessandro Maria Vannucchi

doi:10.3324/haematol.2024.285098

Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib

Haematologica. 2024 Oct 1;109(10):3398-3403. doi: 10.3324/haematol.2024.285098.

Authors

Giacomo Coltro¹, Giulio Capecchi¹, Margherita Maffioli², Francesco Mannelli¹, Barbara Mora³, Alessandro Atanasio¹, Alessandra Iurlo⁴, Chiara Maccari¹, Mirko Farina⁵, Elena Nacca¹, Marianna Caramella⁶, Leonardo Signori¹, Miriam Borella¹, Lorenza Bertù⁷, Maria Esposito¹, Paola Guglielmelli¹, Francesco Passamonti³, Alessandro Maria Vannucchi⁸

Affiliations

¹ Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence.
² Hematology Unit, ASST Sette Laghi, Ospedale di Circolo, Varese.
³ Hematology Division, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan.
⁴ Hematology Division, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan.
⁵ Hematology Unit, ASST Spedali Civili di Brescia, Brescia.
⁶ Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan.
⁷ Department of Medicine and Surgery, University of Insubria, Varese.
⁸ Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence. [email protected].

No abstract available

Publication types

Letter

MeSH terms

Aged
Female
Humans
Male
Middle Aged
Nitriles* / therapeutic use
Prognosis
Pyrazoles* / therapeutic use
Pyrimidines* / therapeutic use
Treatment Outcome

Substances

ruxolitinib
Nitriles
Pyrimidines
Pyrazoles

Grants and funding

Funding: This project has been supported by grants from the Ministero della Salute, Rome, Italy (Finalizzata 2018, NET-2018-12365935, “Personalized medicine program on myeloid neoplasms: characterization of the patient’s genome for clinical decision making and systematic collection of real world data to improve quality of health care”); from Associazione Italiana per la Ricerca sul Cancro (AIRC) 5×1000, Italy (project #21267, “Metastatic disease: the key unmet need in oncology” to MYNERVA (MYeloid NEoplasms Research Venture AIRC)”); and from Fondazione Matarelli, Milan, Italy.